Seoul Clinical Laboratories and Seoul Medical Science Institute

Seoul, South Korea

Seoul Clinical Laboratories and Seoul Medical Science Institute

Seoul, South Korea
SEARCH FILTERS
Time filter
Source Type

Lee B.K.,Eulji University | Song Y.R.,Eulji University | Kim M.Y.,Catholic Kwandong University | Yang J.H.,Catholic Kwandong University | And 7 more authors.
Epidemiology and Infection | Year: 2010

Between January 2006 and May 2008, 2624 pregnant S. Korean women between 35-37 weeks gestation were screened for group B streptococcus (GBS). Resistance to antimicrobials was tested by disk diffusion and serotype determined using co-agglutination assays and microarray methods. Overall, 8% of pregnant women were colonized. Serotype III was the predominant serotype (438%), followed by serotypes V (203%), Ia (121%), and Ib (95%). GBS was frequently resistant to clindamycin (540%) and erythromycin (256%); 37% were resistant to cefazolin. More than three-quarters of serotype V were resistant to clindamycin or erythromycin or both, and 71% of serotype III were resistant to clindamycin but only 12% were resistant to erythromycin. GBS prevalence exceeded earlier reports by one-third. This is the first report of cefazolin resistance in Korea. These results underscore the need to establish screening measures and chemoprophylaxis guidelines regarding GBS infections in Korea. © 2009 Cambridge University Press.

Loading Seoul Clinical Laboratories and Seoul Medical Science Institute collaborators
Loading Seoul Clinical Laboratories and Seoul Medical Science Institute collaborators